An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD

CNS Spectrums

Volumn 10, Issue 12 SUPPL. 20, 2005, Pages 26-34

  Goodman, David W ^a   Ginsberg, Lawrence ^b   Weisler, Richard H ^b   Cutler, Andrew J ^b   Hodgkins, Paul ^b  

^a Johns Hopkins   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; PSYCHOSTIMULANT AGENT;

ADULT; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; FATIGUE; FEMALE; HEADACHE; HEALTH STATUS; HUMAN; HYPERACTIVITY; HYPERTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SIDE EFFECT; SOCIAL STATUS; SUSTAINED RELEASE PREPARATION; TACHYCARDIA; WEIGHT REDUCTION; XEROSTOMIA;

EID: 29444446668     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900002418     Document Type: Article

References (21)

1. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162-170.
2. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adobe Psychiatry. 1997;36(10 suppl):85S-121S.
3. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1996;35(3):343-351.
4. Kessler RC. Prevalence of adult ADHD in the United States: results from the National Comorbidity Survey Replication (NCS-R). Presentation at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
5. Faraone SV, Biederman J, Spencer T, et al. Dose-response efficacy of mixed amphetamine salts XR in adults with ADHD. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
6. United States Census Bureau: Census 2000 Summary File 4. Available at: http://fact-finder.census.gov. Accessed August 16, 2004.
7. Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692-700.
8. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(suppl 12):10-15.
9. Montano B. Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry. 2004;65(suppl 3):18-21.
10. Beck C, Silverstone P, Glor K, et al. Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey. Can J Psychiatry. 1999;44(7):680-684.
11. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434-443.
12. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 1999;19(3):257-264.
13. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775-782.
14. Weisler RH, Biederman J, Spencer T, et al. Adderall XR dosed once daily in adult patients with ADHD. Presentation at: the 156th Annual Meeting of the American Psychiatric Association; May 20, 2003; San Francisco, CA.
15. Biederman J. Mixed amphetamine salts XR in adults with ADHD: 18-month interim analysis. Presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
16. Biederman J, Mick E, Faraone SV. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816-818.
17. Diagnostic and Statistical Monual for Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
18. DuPaul GJ, Power T, Anastopoulos A, Reed R. The ADHD Rating ScA-IV Checklist, Norms and Clinical Interpretation. New York, NY: Guilford Press; 1998.
19. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):46-50.
20. Jensen P. Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder. J Atten Disord. 2002;6(suppl 1):S45-S56.
21. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42(4):424-433.